NCT06128551: Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 534 planned
- Started
- 14 Nov 2023
- Primary completion
- Dec 2028
- Arms
- Daraxonrasib + Elironrasib Combination
- Results
- None posted
- 13 Nov 2023: Trial registered
- 14 Nov 2023: Trial started